- No public price.
- Not disclosed
- Not disclosed
- —
- —
Population health
Verily Lightpath
by Verily
Personalized chronic-care program for cardiometabolic conditions, sold to health plans and employers. Successor to Onduo.
On this page
11/100Tracked
- Regulatory & Compliance0/22
No FDA clearance listed
- Clinical Integration0/31.8
No EHR integrations listed
- Evidence Strength0/20
No peer-reviewed coverage
- Vendor & Market9/24
Early-stage company
- Sentiment & Transparency3/15
Pricing on request, no public amounts
▸ Show all 11 dimensions▾ Hide dimension detail
- FDA clearance0/12
No FDA clearance listed
- HIPAA / SOC2 / BAA0/10
No public HIPAA/SOC2/BAA attestation
- EHR integrations (count)0/18
No EHR integrations listed
- Top-3 EHR coverage (Epic / Oracle / Athena)0/10
None of the top-3 EHRs covered
- Bidirectional write-back0/4
No bidirectional write-back documented
- Peer-reviewed papers0/14
No peer-reviewed coverage
- RCT / meta-analysis / systematic review0/6
No RCT, meta-analysis, or systematic review
- Funding & adoption signal9/18
Early-stage company
- Years in market0/6
Founded year not recorded
- Clinician sentiment (Reddit)0/9
No clinician sentiment data available
- Pricing transparency3/6
Pricing on request, no public amounts
Personalized chronic-care program for cardiometabolic conditions, sold to health plans and employers. Successor to Onduo.
No public price.
Bottom line
Verily Lightpath is a virtual cardiometabolic care programme sold to health plans and employers, with health coaches, licensed clinicians and an AI helper behind it. Members enrol through a benefit. A clinician does not log in and use it as software. The programme supports GLP-1 use and continuous glucose monitoring, and no outcome data for Lightpath is published.
Who is behind Lightpath?
Verily announced Lightpath on 11 June 2024 as "a personalized chronic care solution", starting with Lightpath Metabolic. It succeeds Onduo, the diabetes programme Verily ran with Sanofi until Sanofi pulled back. A Tennessee state benefits page says Onduo became unavailable after 25 August 2025, and Verily's own page carries an Onduo discontinuation notice.
Verily raised USD 300 million in a round led by Series X Capital, announced on 19 March 2026, with UCHealth and the University of Colorado Anschutz taking part. It is no longer controlled by Alphabet, which stays on as a minority investor. Verily's homepage calls the company "AI-native precision health".
What does it do?
Lightpath is built from four modular programmes: Metabolic Intensive, Weight Loss Intensive, Metabolic Improvement and Metabolic Achievement. Members work with health coaches and a clinical team of endocrinologists, pharmacists, primary care physicians, nurses and dietitians. Telemedicine visits and medication review are included, though not in every state. There is an AI helper for members and an AI assistant for clinical staff.
The programme supports GLP-1 use and continuous glucose monitoring, and Weight Loss Intensive includes anti-obesity medication where available. A HLTH summary lists diabetes, hypertension, obesity and hyperlipidaemia as covered conditions. Verily says Lightpath is not intended to replace routine primary care. Open enrolment was planned for early 2026, with Onduo members migrating in late 2025. Whether it has launched inside customer benefit plans is not stated.
What outcome data exists?
Verily cites a peer-reviewed four-month study, but of Onduo, and the announcement gives no citation. No outcome data for Lightpath and no customer counts are published. STAT covered the GLP-1 pivot in June 2024.
What does it cost, and what is certified?
Contracts are negotiated with plans and employers, and no price is public.
Verily's homepage promises "rigorous security, privacy, and auditability protocols" and names no certification. HIPAA, BAA, SOC 2 and HITRUST status are not stated. No FDA clearance covers Lightpath.
Who should look at it?
A benefits director weighing diabetes and weight programmes would be dealing with an independent company, funded in March 2026, whose programme includes clinicians and medication support. Public sources give no evidence that Lightpath outperforms Onduo or any rival. A physician cannot refer a patient straight to it, since access runs through a contracted plan or employer.
The verdict
Lightpath is a GLP-1-aware cardiometabolic programme from Verily, which became independent of Alphabet in March 2026. Its results are not published.
Editorial review last generated October 15, 2026. Synthesized from clinician sentiment, peer-reviewed coverage, and our editorial silo picks. Refined by hand where vendor facts change.
What it costs
All tiers are custom-quoted. The vendor does not publish per-provider list pricing.
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Employer and health-plan contracts | — | — | No public price. |
Source: vendor pricing page. Last checked October 15, 2026.
Other population health
See the full population health ranking
Innovaccer Healthcare Intelligence
by Innovaccer
The Agentic Cloud for Healthcare: a data platform with AI agents for care coordination, revenue cycle and population health.
No public price. The homepage shows none.
Optum Population Health
by Optum
Optum's value-based care software and services for payers and providers, including Value Connect, the ACO Solution and Symmetry.
No public price. Contracts are enterprise-negotiated.
Healthy
by Healthy (formerly ClosedLoop)
Healthcare AI platform that automates predictive model development for payers, providers and ACOs. Also offers a consumer health app.
No public price. A 2023 release described the ACO-Predict risk-stratification product as free. Current availability was not checked.
Health Catalyst
by Health Catalyst
Data and analytics platform for health systems (Ignite), with population health, value-based care and regulatory solutions.
No public price. The homepage shows none.